The study aims to collect data on the influence of a treatment with Visanne (Dienogest 2mg/d) on the Endometriosis related quality of life. These data will be collected using a special patient questionnaire (Endometriosis Health Profile 5, EHP-5). The study will also be used to describe the basic disease status and demographic characteristics of patients searching treatment by a gynecologist because of their endometriosis. In addition, the study will give insight into the typical diagnostic measures the physicians in different countries are using in the field of endometriosis.
Study Type
OBSERVATIONAL
Enrollment
3,006
Intake of Dienogest 2mg/day to treat Endometriosis according to regular clinical practice.
Unnamed facility
Many Locations, Belarus
Unnamed facility
Many Locations, Egypt
Unnamed facility
Many Locations, Jordan
Unnamed facility
Many Locations, Kazakhstan
Percentage of patients, who show an improvement of the EHP-5 items
Time frame: after 6 months of treatment
Mean changes of EHP-5 items by using scores for pre-defined categories
Time frame: after 6 months of treatment
Baseline demographic characteristics and disease status of patients with endometriosis treated with Visanne
Time frame: Baseline
Patient reported severity of endometriosis related pain
Time frame: Baseline and after 6 months of treatment
Reasons for treatment discontinuation
Time frame: after 6 months of treatment
Safety variables will be summarized using descriptive statistics based on adverse events collection
Time frame: after 6 months of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Many Locations, Kuwait
Unnamed facility
Many Locations, Lebanon
Unnamed facility
Many Locations, Qatar
Unnamed facility
Many Locations, Russia
Unnamed facility
Many Locations, Saudi Arabia
Unnamed facility
Many Locations, Ukraine
...and 1 more locations